From the publishers of JADPRO

DLBCL Resource Center

Advertisement

Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?

Last Updated: Monday, November 15, 2021

This review article discusses the safety and effectiveness of CD19-directed CAR T-cell therapy lisocabtagene maraleucel in the treatment of relapsed or refractory DLBCL, including data from the Transcend NHL 001 trial.

Hematology/Oncology and Stem Cell Therapy
Advertisement
News & Literature Highlights
Advertisement
Advertisement